Appeal No. 2006-3253 Page 2
Application No. 10/276,547
The specification discloses a “human dopamine-like G protein-coupled receptor.”
Page 8, line 18. “Human DA-like GPCR is 30% identical over 350 amino acids to the
D. melanogaster protein . . . annotated as a dopamine 1 receptor precursor.” Page 10,
lines 7-9. The disclosed GPCR has the amino acid sequence shown in SEQ ID NO:2.
See page 11, lines 7-9.
The specification discloses “assays for screening test compounds which bind to
or modulate the activity of a DA-like GPCR polypeptide. . . . A test compound
preferably binds to a DA-like GPCR polypeptide.” Page 36, lines 28-31. The
specification states that “compounds which activate a GPCR may be employed for
therapeutic purposes, such as the treatment of asthma, Parkinson’s disease, acute
heart failure, urinary retention, and osteoporosis. In particular, compounds which
activate GPCRs are useful in treating various cardiovascular ailments. . . . In addition,
these compounds may also be used in treating various physiological disorders relating
to abnormal control of fluid and electrolyte homeostasis.” Page 49, lines 1-8.
The specification also states that
regulation of DA-like GPCR can be used to treat anxiety, depression,
hypertension, migraine, compulsive disorders, schizophrenia, autism,
neurodegenerative disorders, such as Alzheimer’s disease, Parkinsonism,
and Huntington’s chorea, and cancer chemotherapy-induced vomiting, as
well as sleep and eating disorders, pain control, disorders involving
regulation of body temperature and blood pressure.
. . . [A]gents which modulate this gene . . . or its products are useful for
treating obesity, overweight, anorexia, cachexia, wasting disorders,
appetite suppression, appetite enhancement, increases or decreases in
satiety, modulation of body weight, and/or other eating disorders such as
bulimia.
Page 49, lines 20-29.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007